Ozempic Linked to Higher Employment in Denmark
Adults on subsidised Ozempic for diabetes worked more hours and were more likely to hold jobs, a Danish population study found.
Updated on Nov. 2, 2026 in Weight Loss

Live Poll
Should governments subsidise weight-loss medications like Wegovy for everyday patients?
A study by researchers at NYU Abu Dhabi, using population-wide records from Denmark for 2018 to 2024, found that patients on subsidised Ozempic for diabetes were more likely to be employed and worked more hours. Among patients paying out of pocket for Wegovy used for weight management, the study found no significant increase in the likelihood of entering employment, though employed Wegovy users worked more hours.
Why it matters
The findings suggest that treating metabolic conditions may have labour-market effects beyond health outcomes, which bears on how governments weigh the cost of subsidised medication. The researchers report that additional income tax revenue from higher labour income could partly offset the spending on subsidised diabetes treatment.
The study analysed Danish population records from 2018 to 2024, comparing employment, working hours and earnings before and after individuals began treatment. The effects were estimated with statistical methods intended to separate treatment effects from broader changes in the labour market, and the results were published as a discussion paper rather than a peer-reviewed article.
The players
NYU Abu Dhabi
A university whose researchers conducted the study on GLP-1 treatments and employment outcomes.
Centre for Economic Policy Research
An international economics research network that published the study as a discussion paper.
Abu Dhabi Department of Health
The health authority that is collaborating on ongoing research into the Thiqa obesity programme.
The details
Researchers tracked changes in employment, working hours and earnings for individuals before and after they began treatment, using statistical methods to distinguish treatment effects from wider labour-market shifts. In Denmark, Ozempic for diabetes is subsidised, while patients using Wegovy for weight management pay the full cost themselves, which allowed the study to compare two groups with different access arrangements. The researchers describe the employment and hours effects as associations found in this design rather than a full account of the biological or social pathways involved.
Timeline
Danish population records from 2018 to 2024 were analysed in the study.
The article reporting the findings was published on 2 November 2026.
Health Landscape
GLP-1 medications such as Ozempic and Wegovy have become central to diabetes and weight-management care, and this study adds labour-market outcomes to the body of evidence on their effects. The findings come from a national register setting with differing subsidy rules, so they describe population patterns rather than a universal effect.
The study suggests that access to treatment, including whether it is subsidised, may be linked to employment and working hours, which is worth noting when considering coverage options. Anyone weighing GLP-1 medication for diabetes or weight management should discuss the cost, coverage and expected benefits with their physician.
The takeaway
Treatment access and cost structure may shape not only health outcomes but also work and income, which is a useful factor to consider in discussions about GLP-1 medication. Talk with your physician about whether these medications are appropriate for your situation and how coverage would apply.
Further reading
For broader context on medications and lifestyle approaches, explore the Weight Loss section.
Live Poll
Should governments subsidise weight-loss medications like Wegovy for everyday patients?


